UPC Case Law
Boehringer Ingelheim International GmbH v Zentiva Portugal, LDA.
Order of the UPC Court of Appeal of 13 August 2025, UPC CoA 446/2025
UPC Case Law by Pitch, edited by Bart Lieben · Published
TL;DR
The Court of Appeal granted Boehringer Ingelheim a provisional injunction against Zentiva's nintedanib generics in all 17 UPC states where EP 1 830 843 is in force. It held that completing Portugal's pricing and reimbursement procedure more than a year before patent expiry amounted to an imminent infringement. Generics companies that clear national price and reimbursement steps early now face pre-launch injunctions even before any offer is made.
Key holding
Under Art 62(1) and (4) UPCA and R 206.2(c) RoP, an infringement is imminent where the potential infringer has set the stage, so that infringement is only a matter of starting the action because preparations are fully completed. Applying for or obtaining a marketing authorisation for a generic medicine does not by itself create an imminent infringement. Completing the national procedures for health technology assessment, pricing and reimbursement can do so, assessed against the national regulatory context and the circumstances of the case. Taking part in public procurement with an infringing product is 'offering' under Art 25 UPCA, whether or not national law classifies the procedure as pre-contractual.
Questions decided
- Does applying for or obtaining a marketing authorisation for a generic amount to imminent infringement?
- Can completing pricing and reimbursement procedures amount to imminent infringement?
- Is participation in public procurement 'offering' under Art 25 UPCA?
- Should the draft EU pharma Bolar provision shape the imminence test?
- Can an information order under Art 67 UPCA be granted for a merely imminent infringement?
- Who must prove the content of national law under Art 24 UPCA?
Full summary
Read the full analyses for free — create a free account
With a free Academy account you read the full analysis of every Court of Appeal decision: the facts and procedure, the issues, the court’s reasoning and the practice points. Your name, an e-mail address and a password; no payment, and you can delete the account yourself at any time.
In the same case
More on provisional measures
- Decision · UPC CoA 49/2026
Guardant Health, Inc. v Sophia Genetics SA and others
The Court of Appeal set aside a EUR 600,000 award of representation costs because the successful party had backed it only with invoices reading "supply of legal services" and general assertions about complexity and urgency.
- Order · UPC CoA 61/2026
SharkNinja Operating LLC v Groupe SEB France and others
The Court of Appeal overturned the Paris Local Division and granted SharkNinja a provisional injunction in France and Germany against SEB's "Cookeo Infinity" multicookers.
- Order · UPC CoA 936/2025
Amazon.com, Inc. and others v InterDigital VC Holdings, Inc. and others
The Court of Appeal permitted InterDigital to withdraw its application for provisional measures against Amazon while Amazon's appeal was pending, and declared the proceedings closed.
- Order · UPC CoA 108/2026
AIM Sport Development AG v TGI Sport Suomi Oy and others
The Court of Appeal's judge-rapporteur held that an appeal against a first-instance order disposing of an application for provisional measures is an appeal against a final decision under R 220.1(a) RoP, because R 363.2 RoP gives such orders that status.
- Order · UPC CoA 36/2026
Angelalign Technology Inc. and others v Align Technology, Inc.
The Court of Appeal rejected Angelalign's appeal and upheld the Düsseldorf preliminary injunction against the "Live Now" feature of its iOrtho orthodontic planning software.